Abstract
Ovarian cancer remains a significant cause of cancer-related mortality, with epithelial ovarian cancer (EOC) being the most common subtype. Despite advances in treatment, the 5-year survival rate for late-stage EOC remains low due to factors such as tumor heterogeneity and an immunosuppressive tumor microenvironment (TME). This study investigates the therapeutic potential of chimeric endocrine receptor (CER) T cells engineered to express follicle stimulating hormone (FSH) in a syngeneic mouse model of EOC expressing follicle stimulating hormone receptor (ID8-FSHR). We compared two different co-stimulatory domains—CD28ζ and 4-1BBζ—in FSH-CER T cells and found that FSH-CD28ζ CER T cells exhibited enhanced cytotoxicity, proliferation, and cytokine secretion in vitro and in vivo. In the ID8-FSHR mouse model, FSH-28ζ CER T cells significantly reduced tumor burden and extended survival compared to FSH-hBBζ and control CER T cells. However, the therapeutic efficacy was compromised by T cell exhaustion, with all FSH-CER T cells expressing high levels of exhaustion markers after 7 days. In summary, incorporating a CD28ζ costimulatory domain enhances the efficacy of FSH-CER T cells, highlighting their therapeutic potential in ovarian cancer and supporting the development of strategies to mitigate immune exhaustion.
Introduction
Epithelial ovarian cancer (EOC) is often diagnosed at advanced stages, where the tumor microenvironment (TME) becomes highly immunosuppressive. While Chimeric Antigen Receptor (CAR) T-cell therapies have seen success in hematological malignancies, their application in solid tumors like EOC is hindered by off-target toxicities and poor persistence. This study explores Chimeric Endocrine Receptor (CER) T cells, which utilize natural hormones—specifically follicle-stimulating hormone (FSH)—to target the follicle-stimulating hormone receptor (FSHR) expressed on tumor cells. A critical design choice in these receptors is the co-stimulatory domain, typically CD28 or 4-1BB, which dictates the metabolic and signaling profile of the T cell.
Methods
The researchers utilized a syngeneic ID8-FSHR mouse model to evaluate the efficacy of FSH-targeting CER T cells. Three constructs were compared: FSH-CD28ζ, FSH-4-1BBζ, and a non-functional control. In vitro assessments included real-time cytotoxicity assays (RTCA) and cytokine profiling (IFN-γ and TNF-α). In vivo, tumor progression was monitored via bioluminescence imaging, and survival rates were tracked. To investigate the impact of the TME, the team analyzed the proteomic and metabolic profile of malignant ascites and assessed T cell exhaustion markers (PD-1, LAG-3) following treatment.
Results
The study demonstrated that the CD28 co-stimulatory domain provided superior anti-tumor activity compared to 4-1BB in the context of FSH-CER T cells. In vitro, FSH-CD28ζ cells showed significantly higher cytotoxicity and cytokine secretion. These findings translated to the in vivo model, where mice treated with FSH-CD28ζ CER T cells exhibited a marked reduction in tumor burden and significantly prolonged survival.
Despite the initial success of the CD28-based therapy, the researchers observed that the abdominal environment (ascites) rapidly induced T cell exhaustion. Within seven days of infusion, both CD28 and 4-1BB CER T cells expressed high levels of exhaustion markers like PD-1 and LAG-3. Further analysis suggested that host-derived factors in the ascites, potentially including endogenous antibodies, interfere with the FSH-FSHR interaction, specifically inhibiting CER T cell function.
Conclusion
The inclusion of a CD28 co-stimulatory domain significantly enhances the immediate potency and therapeutic efficacy of FSH-targeting CER T cells in ovarian cancer models. However, the rapid onset of T cell exhaustion within the immunosuppressive TME remains a major hurdle. Future strategies may involve "armoring" these T cells to resist exhaustion or combining CER T therapy with checkpoint inhibitors to sustain the anti-tumor response.
Summary updated